X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
index medicus (78) 78
male (78) 78
female (77) 77
middle aged (71) 71
hematology (68) 68
aged (64) 64
adult (60) 60
oncology (52) 52
rituximab (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (44) 44
chemotherapy (42) 42
prognosis (39) 39
treatment outcome (37) 37
lymphomas (32) 32
therapy (27) 27
aged, 80 and over (26) 26
disease-free survival (26) 26
retrospective studies (25) 25
neoplasm staging (23) 23
non-hodgkins-lymphoma (23) 23
survival (23) 23
adolescent (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
follow-up studies (19) 19
young adult (18) 18
cancer (17) 17
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
fluorodeoxyglucose f18 (16) 16
cyclophosphamide - administration & dosage (15) 15
doxorubicin - administration & dosage (15) 15
survival analysis (15) 15
care and treatment (14) 14
cyclophosphamide (14) 14
disease (14) 14
medicine & public health (14) 14
vincristine - administration & dosage (14) 14
analysis (13) 13
lymphoma (13) 13
positron-emission tomography (13) 13
predictive value of tests (13) 13
survival rate (13) 13
hemic and lymphatic diseases (12) 12
hodgkin disease - drug therapy (12) 12
italy (12) 12
lymphoma, large b-cell, diffuse - drug therapy (12) 12
prednisone - administration & dosage (12) 12
prospective studies (12) 12
recurrence (12) 12
antibodies, monoclonal, murine-derived - administration & dosage (11) 11
b-cell lymphoma (11) 11
doxorubicin (11) 11
hodgkin disease - diagnostic imaging (11) 11
non-hodgkin's lymphomas (11) 11
patients (11) 11
positron emission tomography (11) 11
positron-emission-tomography (11) 11
radiotherapy (11) 11
trial (11) 11
abridged index medicus (10) 10
antibodies, monoclonal - administration & dosage (10) 10
antibodies, monoclonal, murine-derived (10) 10
drug therapy (10) 10
lymphoma, follicular - pathology (10) 10
lymphoma, large b-cell, diffuse - mortality (10) 10
radiopharmaceuticals (10) 10
toxicity (10) 10
antineoplastic agents - therapeutic use (9) 9
doxorubicin - therapeutic use (9) 9
drug administration schedule (9) 9
fdg-pet (9) 9
hodgkin disease - pathology (9) 9
kaplan-meier estimate (9) 9
positron-emission tomography - methods (9) 9
risk factors (9) 9
antibodies, monoclonal, murine-derived - therapeutic use (8) 8
chop (8) 8
combined modality therapy (8) 8
diagnosis (8) 8
fludarabine (8) 8
follicular lymphoma (8) 8
hodgkin's disease (8) 8
lymphoma, follicular - drug therapy (8) 8
lymphoma, large b-cell, diffuse - pathology (8) 8
lymphoma, non-hodgkin - drug therapy (8) 8
response criteria (8) 8
time factors (8) 8
transplantation (8) 8
antineoplastic agents (7) 7
antineoplastic agents - administration & dosage (7) 7
combination (7) 7
hematology, oncology and palliative medicine (7) 7
hodgkin disease - diagnosis (7) 7
lymphoma, follicular - mortality (7) 7
lymphoma, non-hodgkin - mortality (7) 7
multivariate analysis (7) 7
pet imaging (7) 7
phase-ii (7) 7
regimen (7) 7
tomography (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 06/2019, Volume 9, Issue 1, pp. 8586 - 12
The definition of the gene expression profile of genes encoding Ion Channels and Transporters (ICT-GEP) represents a novel and attracting aspect in cancer. We... 
CELLS | MULTIDISCIPLINARY SCIENCES | SUBSETS | PREDICTS SURVIVAL | PROLIFERATION | LEUKEMIAS | NF-KAPPA-B | Glucose transporter | Oxidative metabolism | Excitability | Potassium channels | Gene expression | Drug resistance | Metabolism | Potassium channels (calcium-gated) | Overexpression | DNA microarrays | Lymphocytes B | Glycolysis | Metabolic pathways | Lymphomas | Ion channels | B-cell lymphoma
Journal Article
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 9, pp. 2066 - 2073
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 17, pp. 1769 - 1775
Purpose To assess the role of [F-18] fluorodeoxyglucose ([F-18] FDG) positron emission tomography/computed tomography (PET/CT) after rituximab and... 
NON-HODGKINS-LYMPHOMA | ONCOLOGY | PET | CHEMOTHERAPY
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 8, pp. 950 - 956
Journal Article